High-dose combination alkylating agent chemotherapy with autologous bone marrow support for metastatic XXXX .

@entity1 @entity0 @entity5 @entity900 @entity786 @entity204
Seventeen @entity1 with metastatic @entity0 were treated with a high-dose combination chemotherapy regimen and autologous bone marrow support. Thirteen @entity1 had prior combination chemotherapy. Fifteen @entity1 were treated with a phase II regimen of @entity786 (5.625 g/m2), @entity900 (165 mg/m2), and BCNU (600 mg/m2). Bone marrow harvest and reconstitution were uncomplicated. All @entity1 became profoundly myelosuppressed. Fourteen of 16 evaluable @entity1 (88%) responded, including six complete responses (CRs) (38%). The median time to @entity5 progression was 5 months. The median survival was 8 months. CRs occurred more frequently in @entity1 with no prior chemotherapy for metastatic disease, @entity0 ; and @entity1 treated within 3 months of first recurrence. The rate of @entity5 regression was rapid, with a median of 11 days to partial response (PR) and 12 days to CR. Those @entity1 achieving a PR by day 7 had a greater likelihood (P = .03) of attaining a CR than those @entity1 whose PR occurred later. Three @entity204 (18%) occurred, all in @entity1 with @entity0 treated with prior chemotherapy. High-dose combined alkylating agent therapy produced high PR and CR rates in metastatic @entity0 @entity1 , most of whom had failed prior chemotherapy. The rate of @entity5 regression was rapid. Current efforts are directed at developing a regimen using drugs specifically active in @entity0 , with an intent of combining an effective high-dose regimen with additional modalities of therapy in the treatment of @entity0 .
